Recent Updates
Recently added Catalysts

TachoSil, Current Practice

Phase 3

Cerebrospinal Fluid Leaks | Unknown | Other |Takeda Pharmaceutical Company Limited|Last Updated: Jul 25, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment726
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01355627TASALL - TachoSil® Against Liquor LeakPHASE3 COMPLETED 726Apr 1, 2011Jun 1, 2013Jul 25, 201439 Austria, Belgium +9
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With Clinically Evident Verified Post-Operative Cerebrospinal Fluid Leak or Clinically Evident Pseudomeningocele or Treatment Failure
Up to 8 Weeks (7 Weeks ± 1 Week)

An assessment was performed daily from randomization to Day of Discharge and at the Efficacy Follow-up visit at week 7 ± 1 week. Clinically evident cerebrospinal fluid leak was confirmed by: 1. Glucose concentration test and/or 2. β-2-transferrin test. A clinically evident pseudomeningocele was considered to be present post-operatively if the following criteria were fulfilled: 1. A subcutaneous, visible/palpable fluctuant fluid accumulation was noted at the site of the surgical incision or adjacent to it; 2. It is suspected the fluid accumulation is cerebrospinal fluid. A treatment failure was defined as application of a new and/or different treatment after application of the study treatment or a third application of (or part of) the selected study treatment on the outside of the dura.

Secondary Endpoints
Percentage of Participants With Post-Surgical Non-Clinically Evident Post-Operative Pseudomeningocele
Assessment at least once prior to discharge from neurosurgical ward, with the expected discharge from neurosurgical ward after an average of 10 days (Up to 28 Weeks)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TachoSil®EXPERIMENTAL -
Current practice groupACTIVE_COMPARATOR -
Interventions
NameTypeDescription
TachoSil®PROCEDUREPrimary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
Current PracticePROCEDUREPrimary suture must be performed. Duraplasty may be performed at the discretion of the investigator. In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites39

Main Inclusion Criteria (Positive response): • Is the surgical approach/procedure consistent with skull base surgery? I.e. one of the following: * Lateral approach to the foramen magnum: Far lateral, extreme lateral, anterolateral, posterolateral * Approach to the jugular foramen: Infratemporal, j...

Countries:AustriaBelgiumFranceGermanyGreeceItalyNetherlandsPolandRussiaSpainSweden
Unlock Eligibility Criteria